Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Live Nation Entertainment, Inc. (LYV) vs Revvity Inc (RVTY) Price & Performance

Live Nation Entertainment, Inc.Trade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Live Nation Entertainment, Inc. vs Revvity Inc — how do they compare? Live Nation Entertainment, Inc. trades at $170.33 (market cap $39.92B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.4× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Revvity Inc for 12 Days on average.

LYVRVTY
Market Cap
$39.92B$16.98B
Volume
1,982,6091,456,900
Sector
MediaHealth
52-Week High
$188.46$157.36
52-Week Low
$125.61$82.26
Typical Hold Time
72 Days12 Days
Enterprise Value
$42.13B$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Live Nation Entertainment, Inc.

Live Nation Entertainment (LYV) trades at $171.34, up 0.29% with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 earnings with a beat on EPS but faces valuation concerns with a P/E of 117.49 and negative ROE of -116.65%. Recent news highlights strong consumer demand for live events and strategic partnerships, though insider selling and regulatory scrutiny present headwinds.

The outlook remains positive with 87% analyst buy ratings and a $208.18 price target, representing 21% upside. Key risks include high debt levels, margin pressure, and ongoing regulatory challenges. Revenue growth continues with 2026 projections of $26.3B, but profitability metrics need improvement for sustained shareholder value.

Revvity Inc

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LYV

No sentiment data available yet.

RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About Live Nation Entertainment, Inc.

Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.

Read more on LYV →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →